The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
This issue brief describes how Medicare beneficiaries navigate the Medicare Part D exceptions, appeals, and grievances processes to get access to medically necessary prescriptions not covered under their Medicare prescription drug plans. It identifies and describes policy issues that may make it difficult for beneficiaries to utilize the processes. Issue Brief (.pdf)
These toplines provide the complete results from a comprehensive survey of seniors on their understanding of and views toward the Medicare drug benefit. The survey of 802 seniors was conducted in late October 2005, prior to the start of the benefit's open enrollment period, which runs from Nov. 15, 2005 to May 15, 2006. The survey was conducted and analyzed by researchers at the Kaiser Family Foundation and the Harvard School of Public Health. It…
Two national surveys conducted and analyzed by the Kaiser Family Foundation show that substantial majorities of pharmacists and physicians believe that the prescription drug law is helping people on Medicare save money on their medications. At the same time, a majority in both professions report that Medicare beneficiaries who they see are encountering problems in getting their medications, sometimes with serious consequences. The questions about Medicare drug plans were part of surveys designed and analyzed…
These toplines provide the results of a 2006 national survey of pharmacists on their views and experiences related to the new Medicare drug benefit. Topline (.pdf)
The survey, which assessed seniors' views of and experiences with the Medicare drug benefit, was conducted November 9-19 by the Kaiser Family Foundation and the Harvard School of Public Health. It included a nationally representative sample of 718 seniors, including 275 who reported being enrolled in a Medicare drug plan. The questions about experiences under the Medicare drug benefit were part of a larger survey of 1,867 adults on the public's health agenda for Congress…
This issue brief describes Medicare drug benefit policy issues for residents of nursing homes and other long-term care settings, such as assisted living facilities and board and care facilities. The brief addresses differing rules for nursing home and non-nursing home settings, as well as for dual eligibles residing in long-term care facilities. Issue Brief (.pdf)
Findings from the Kaiser/Hewitt 2005 Survey on Retiree Health Benefits The 2005 Kaiser/Hewitt survey of large businesses that provide retiree health benefits to their workers assesses their responses to the new Medicare drug benefit in 2006, their plans for the future, and the way these changes affect retirees. It also looks at the rising costs and changing benefits of retiree health coverage overall in 2005. News Release Report Chartpack Materials from the December 7, 2005…
More than two years ago President Biden signed into law Medicare drug pricing provisions in the Inflation Reduction Act. KFF's September Health Tracking Poll examines voter's views on these provisions and finds that large majorities of voters are unaware of the provisions despite reporting support for them.
This brief focuses on the stand-alone Medicare Part D prescription drug plan marketplace and its somewhat uncertain future, in light of recent trends in plan availability and the potential for another year of premium increases in 2026, in part depending on what the Trump administration decides to do with the temporary Part D premium stabilization demonstration. The brief explains why the stability of the PDP market matters, both for people in traditional Medicare who want…
This blog post revisits an earlier analysis of the drug Sovaldi (sofosbuvir) using new data released by the Centers for Medicare and Medicaid Services, and considers both the ongoing impact of hepatitis C drugs for Medicare Part D and the broader implications for Medicare of new high-priced drugs entering the market.
© 2026 KFF